Published Online
on December 5, 2005

A more recent version of this article appeared on December 13, 2005

This Article Full Text (PDF) Correction (v113,pe712) All Versions of this Article: 112/24/3795    most recent CIRCULATIONAHA.105.556233v1 Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mason, R. P. Articles by Malinski, T. Search for Related Content PubMed PubMed Citation Articles by Mason, R. P. Articles by Malinski, T. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB NITRIC OXIDE Related Collections Cell signalling/signal transduction Hypertension - basic studies Endothelium/vascular type/nitric oxide Other Vascular biology

Submitted on April 15, 2005
Revised on August 8, 2005
Accepted on September 19, 2005

Nebivolol Reduces Nitroxidative Stress and Restores Nitric Oxide Bioavailability in Endothelium of Black Americans

R. Preston Mason PhD, Leszek Kalinowski MD, PhD, Robert F. Jacob PhD, Adam M. Jacoby BS, and Tadeusz Malinski PhD^*

From the Department of Biochemistry, Ohio University, Athens, Ohio (L.K., A.M.J., T.M.); Elucida Research, Beverly, Mass (R.P.M., R.F.J.); and Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, Mass (R.P.M.). Dr Kalinowski was on sabbatical leave from the University of Gdansk.

^* To whom correspondence should be addressed. E-mail: malinski{at}ohiou.edu.

Background--Alterations in endothelial function may contribute to increased susceptibility of black Americans to cardiovascular disease. The ability to pharmacologically reverse endothelial dysfunction in blacks was tested with nebivolol, a ₁-selective agent with vasodilating and antioxidant properties.

Methods and Results--The effects of nebivolol on endothelial nitric oxide (NO), superoxide (O₂^-), and peroxynitrite concentration (ONOO^-) release were studied in human umbilical vein endothelial cells and iliac artery endothelial cells isolated from age-matched black and white donors. Kinetics and concentrations of NO/O₂^-/ONOO^- were measured simultaneously with nanosensors from single cells and shown to have significant interracial differences. The rate of NO release was 5 times slower in blacks than in whites (94 versus 505 nmol · L^-1 · s^-1), whereas the rates of release were faster by 2 times for O₂^- and 4 times for ONOO^- (22.1 versus 9.4 nmol · L^-1 · s^-1 for O₂^- and 810 versus 209 nmol · L^-1 · s^-1 for ONOO^-). Pretreatment with 1.0 to 5.0 µmol/L nebivolol restored NO bioavailability in endothelial cells from black donors with concurrent reductions in O₂^- and ONOO^- release, similar to levels in the endothelium of whites. The effects of nebivolol were dose-dependent and not observed with atenolol; similar effects were observed with apocynin, an NAD(P)H oxidase inhibitor.

Conclusions--Reduced endothelial NO bioavailability in American blacks is mainly due to excessive O₂^- and ONOO^- generation by NAD(P)H and uncoupled endothelial NO synthase. Nebivolol decreased O₂^- and ONOO^- concentrations and restored NO bioavailability in blacks to the level recorded in cells from whites, independently of ₁-selective blockade.

Key words: cardiovascular diseases • endothelium • nitric oxide • beta-blockers • ethnic groups

This article has been cited by other articles:

				T. Munzel and T. Gori Nebivolol The Somewhat-Different beta-Adrenergic Receptor Blocker. J. Am. Coll. Cardiol., October 13, 2009; 54(16): 1491 - 1499. [Abstract] [Full Text] [PDF]

				A. Maffei and G. Lembo Nitric oxide mechanisms of nebivolol Therapeutic Advances in Cardiovascular Disease, August 1, 2009; 3(4): 317 - 327. [Abstract] [PDF]

				J.-L. Balligand beta(3)-Adrenoceptor stimulation on top of beta(1)-adrenoceptor blockade "Stop or Encore?". J. Am. Coll. Cardiol., April 28, 2009; 53(17): 1539 - 1542. [Full Text] [PDF]

				E. Osto, C. M. Matter, A. Kouroedov, T. Malinski, M. Bachschmid, G. G. Camici, U. Kilic, T. Stallmach, J. Boren, S. Iliceto, et al. c-Jun N-Terminal Kinase 2 Deficiency Protects Against Hypercholesterolemia-Induced Endothelial Dysfunction and Oxidative Stress Circulation, November 11, 2008; 118(20): 2073 - 2080. [Abstract] [Full Text] [PDF]

				M. Korda, R. Kubant, S. Patton, and T. Malinski Leptin-induced endothelial dysfunction in obesity Am J Physiol Heart Circ Physiol, October 1, 2008; 295(4): H1514 - H1521. [Abstract] [Full Text] [PDF]

				L. M. Prisant Nebivolol: Pharmacologic Profile of an Ultraselective, Vasodilatory {beta}1-Blocker J. Clin. Pharmacol., February 1, 2008; 48(2): 225 - 239. [Abstract] [Full Text] [PDF]

				S. Hallstrom, M. Franz, H. Gasser, M. Vodrazka, S. Semsroth, U. M. Losert, M. Haisjackl, B. K. Podesser, and T. Malinski S-nitroso human serum albumin reduces ischaemia/reperfusion injury in the pig heart after unprotected warm ischaemia Cardiovasc Res, February 1, 2008; 77(3): 506 - 514. [Abstract] [Full Text] [PDF]

				E. Mata-Greenwood and D.-B. Chen Racial Differences in Nitric Oxide--Dependent Vasorelaxation Reproductive Sciences, January 1, 2008; 15(1): 9 - 25. [Abstract] [PDF]

				G. Peluffo and R. Radi Biochemistry of protein tyrosine nitration in cardiovascular pathology Cardiovasc Res, July 15, 2007; 75(2): 291 - 302. [Abstract] [Full Text] [PDF]